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Abstract 
Background: We assessed the validity of a self-report measure of undetectable viral load (VL) among women with 
HIV in British Columbia (BC), Canada. Questionnaire data from the Canadian HIV Women’s Sexual and Reproductive 
Health Cohort Study was linked with population-based clinical data from the BC Centre for Excellence in HIV/AIDS. 
Self-reported undetectable VL was assessed by the question: “What was your most recent VL, undetectable (i.e. <50 
copies/mL) or detectable (i.e. ≥50 copies/mL)?” Laboratory measurements of VL <50 copies/mL (closest to/before 
study visit) were the criterion for validity analyses. We measured positive and negative predictive values (PPV, NPV) 
and likelihood ratios (LR+, LR−).
Results: Of 356 participants, 99% were linked to clinical data. Those unlinked (n = 1), missing self-report VL (n = 18), 
or missing self-report and laboratory VL (n = 1) were excluded. Among the remaining 336: median age was 44 (IQR 
37–51); 96% identified as cis-gender; 84% identified as heterosexual; and 45% identified as Indigenous, 40% White, 8% 
African, Caribbean, or Black, and 8% other/multiple ethnicities. Overall, 85% self-reported having an undetectable VL 
while 82% had clinical data indicating viral suppression. The PPV was 93.7 (95% CI 90.2–96.2) indicating that 94% of 
women who self-reported being undetectable truly were. The NPV was 80.4 (95% CI 66.9–90.2). LR+ was 3.2 (2.1–4.6) 
and LR− was 0.05 (0.03–0.10).
Conclusions: Our self-report measure assessing undetectable VL strongly predicted true viral suppression among 
Canadian women with HIV. This measure can be used in research settings without laboratory data in regions with 
high rates of VL testing and suppression.
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Background
Combination antiretroviral therapy (cART) is now rec-
ommended for all people living with HIV regardless of 
CD4 cell count [1]. The clinical benefit of early initiation 
of cART was established in two recent randomized 
controlled trials, START [2] and Temprano [3], which 
reported reduced risks of HIV morbidity and mortal-
ity. Sustained use of and adherence to cART also has the 
additional benefit of lowering the risk of HIV transmis-
sion to zero by suppressing plasma viral load (VL) [4–9].
The efficacy of using treatment for individual 
health and for population-level prevention has been 
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demonstrated in jurisdictions around the world includ-
ing British Columbia (BC), Canada, where “Treatment 
as Prevention” (TasP) was formally adopted into policy 
in 2010 [10]. This has resulted in new global targets for 
reducing the burden of HIV worldwide. According to 
United Nations three-part “90–90–90” strategy, the goal 
is to have, by 2020, 90% of all people living with HIV 
diagnosed, 90% of all people diagnosed with HIV on 
cART, and 90% of all people on cART virally suppressed 
[11].
To monitor and evaluate progress on 90–90–90 goals, 
accurate assessment of viral suppression is essential. 
Laboratory technologies of plasma samples are the gold 
standard for measuring VL in clinical practice [12]. How-
ever, in the absence of linkage to clinical data, observa-
tional studies must rely on participant self-report of VL 
and it is unclear whether this is a valid method of assess-
ment. In this analysis, we investigated the validity of 
using a brief survey question capturing most recent VL 
as a way to estimate viral suppression among a cohort of 
women living with HIV in BC, using linked questionnaire 
and clinical data from the Canadian HIV Women’s Sexual 
and Reproductive Health Cohort Study (CHIWOS).
Methods
The study
CHIWOS is a national, multi-site, longitudinal, commu-
nity-based research study conducted by, with, and for 
women living with HIV, in collaboration with research-
ers, clinicians, service providers, policy-makers and other 
stakeholders (described in detail elsewhere: [13]). In total, 
1425 self-identified women living with HIV (≥16  years) 
were enrolled into the study from three Canadian prov-
inces: BC (n  =  356), Ontario (n  =  713), and Québec 
(n = 356).
Procedures
Participants completed structured questionnaires at 
baseline, administered by Peer Research Associates 
(women living with HIV who have received training in 
community-based research) [14]. Study visits were 1.5 
to 2.5  h long (median: 120  min, IQR 90–150) and took 
place in various community settings such as HIV clin-
ics, AIDS Service Organizations, women’s homes, or 
via phone/Skype [15]. Questionnaires were web-based, 
developed using FluidSurveys™ software and designed to 
collect nationally consistent self-reported data on socio-
demographics, use of HIV clinical and support services, 
and health outcomes including most recent VL. In BC, 
linkage to clinical data was possible through the Drug 
Treatment Program (DTP) of the BC Centre for Excel-
lence in HIV/AIDS, a population-based registry captur-
ing 100% of laboratory-confirmed VL data for all people 
living with HIV and receiving cART in BC. Linkage will 
be endeavored in other study provinces via the Canadian 
HIV Cohort (CANOC) Collaborative Research Centre 
[16], although incomplete linkage is expected due to var-
ying study eligibility criteria and the absence of a single, 
coordinated population-based registry in Ontario and 
Québec.
Final sample for this analysis
For this analysis, we used baseline questionnaire data 
from participants enrolled in CHIWOS in BC between 
August 27, 2013 and May 1, 2015, and linked clinical data 
from the BC Centre for Excellence in HIV/AIDS. Of 356 
participants, 99% were linked to the DTP clinical data-
base (n =  354). Those who remained unlinked (n =  1), 
who provided invalid responses (i.e., “don’t know” or “pre-
fer not to answer”) to the survey question assessing VL 
or self-reported never receiving HIV medical care or VL 
results (n = 18), or who were missing both self-reported 
and laboratory VL (n = 1) were excluded from the analy-
sis, leading to a final analytic sample of 336.
Main outcome
In the CHIWOS questionnaire, self-reported VL was 
assessed by the following survey question: “What was 
your most recent viral load, undetectable (i.e. below 50 
copies/mL) or detectable (i.e. 50 copies/mL or more)?” 
Criteria for validity analyses were corresponding labo-
ratory measurements of VL  <50 copies/mL, with tests 
closest to and before the study visit selected for analysis. 
For those included in analyses (N =  336), median time 
between study visit and most recent VL lab result was 
50.5 days (IQR 20.5–87).
Statistical analyses
Baseline characteristics of the sample were estimated. 
Following this, positive and negative predictive val-
ues (PPV, NPV) and likelihood ratios (LR+, LR−) were 
computed for the outcome, overall and stratified by 
select socio-demographic variables including ethnicity 
(Indigenous vs. White vs. African, Caribbean, or Black 
vs. other/multiple ethnicities), education (<High school 
vs.  ≥High school), and illicit drug use within the past 
3  months (Yes vs. No). PPV is the probability that par-
ticipants who self-report being “undetectable (i.e., below 
50 copies/mL)” truly have laboratory measurements 
of VL <50 copies/mL, while NPV is the probability that 
participants who self-report being “detectable (i.e., above 
50 copies/mL)” truly have laboratory measurements of 
VL  ≥50 copies/mL [17]. LR+  (sensitivity/1-specificity) 
corresponds to the clinical concept of “ruling-in disease”, 
and indicates how much a “positive test” (in this case, 
self-reported undetectable VL) increases the odds that a 
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patient actually has the health outcome (in this case, true 
suppression) [18]. LR− (1-sensitivity/specificity) corre-
sponds to “ruling-out disease”, and indicates how much a 
“negative test” (in this case, self-reported detectable VL) 
decreases the odds that a patient has the health outcome 
(in this case, true suppression) [18]. LRs greater than 1 
indicate that true suppression is likely (the larger the 
number, the more likely suppression), while LRs between 
0 and 1 indicate that suppression is unlikely (the closer 
the number to zero, the less likely suppression) [18]. 
Analyses were conducted using SAS version 9.4 (SAS, 
North Carolina, United States).
Ethical statement
All Principal Investigators’ institutional Research Ethics 
Boards granted ethical approval including Women’s Col-
lege Hospital, McGill University Health Centre, and in 
BC, Simon Fraser University and the University of Brit-
ish Columbia/Providence Health (ethical approval num-
bers: 2012s0959 and H12-03326). Ethical approval was 
also sought and granted from hospitals and AIDS Service 
Organizations if recruitment occurred there. All par-
ticipants provided consent (written or oral in the case of 
phone interviews) to participate.
Results
Baseline characteristics of the sample
Among the 336 women included in this analysis, 99% 
self-reported accessing HIV medical care in the past 
year and 96% self-reported currently taking cART. Over-
all, 85% (n = 286) self-reported having undetectable VL 
and 82% (n = 276) had laboratory data indicating VL <50 
copies/mL.
Baseline characteristics of the sample are provided in 
Table  1. Median age was 44 (IQR 37–51). The majority 
of women identified as cis-gender (96%) and hetero-
sexual (84%). Forty-five percent identified as Indigenous 
and 40% as White; a small proportion also identified as 
African, Caribbean, or Black (8%), or other/multiple eth-
nicities (8%). Most completed at least high school (73%) 
yet reported low annual household incomes of <$20,000 
(72%). Thirty-four percent reported illicit drug use in the 
past 3 months, and 9% were incarcerated in the past year.
Validity analyses of viral load data taken 
from questionnaires and laboratory results
Results of validity analyses are provided in Tables  2 
(overall sample) and 3 (sub-populations). For the overall 
sample, the PPV was 93.7 (95% CI 90.2–96.2), indicat-
ing that 93.7% of women who self-reported being unde-
tectable via questionnaire truly were virally suppressed 
according to laboratory results. The NPV was 80.4 (95% 
CI 66.9–90.2), suggesting that 80.4% of women who 
self-reported being detectable truly were not virally sup-
pressed according to laboratory results. The LR+ was 3.2 
(95% CI 2.1–4.6), indicating that self-reporting unde-
tectable offers a moderate increase in the likelihood of 
true suppression. The LR− was 0.05 (95% CI 0.03–0.10), 
suggesting that reporting a detectable VL provides a 
large and conclusive decrease in the likelihood of true 
suppression. In terms of specific sub-populations, no 
significant differences in PPVs were observed, with point 
estimates ranging from 90.4 to 96.0 (and overlapping 
confidence intervals) across select socio-demographic 
variables including ethnicity, education, and recent illicit 
drug use. Some variations in point estimates, though, 
were seen in NPVs. For instance, those who had com-
pleted high school had a higher NPV [84.4 (95% CI 
67.2–94.7)] compared with those who did not [73.7 (95% 
CI 48.8–90.9)]; while the confidence intervals were large 
and overlapped owing to small cell sizes and low power, 
the differing effect estimates suggest education level may 
be a marker for accurate reporting of detectable VL. 
Illicit drug use was not a marker, however. The values of 
likelihood ratios (LR+  and LR−) were similar to those 
found with the overall sample.
Table 1 Baseline characteristics of  women with  HIV 
enrolled in  British Columbia in  the CHIWOS Study 
(n = 336)
VL viral load, cART combination antiretroviral therapy, LGBTQ lesbian/gay/
bisexual/two-spirited/queer, CHIWOS Canadian HIV Women’s Sexual and 
Reproductive Health Study
n (%)
Clinical variables
 Self-reported HIV medical care in past year (yes) 333 (99)
 Self-reported current cART use (yes) 323 (96)
 Self-reported undetectable VL (yes) 286 (85)
 Laboratory-confirmed VL <50 copies/mL (yes) 276 (82)
Socio-demographic variables
 Age, median (IQR) 44 (IQR 37–51)
 Gender identity
  Cis gender 323 (96)
  Trans and gender diverse women 13 (4)
 Sexual orientation
  Heterosexual 281 (84)
  LGBTQ 55 (16)
 Ethnicity
  Indigenous 151 (45)
  White 133 (40)
  African/Caribbean/Black 26 (8)
  Other ethnicities 26 (8)
 ≥High school education (yes) 245 (73)
 <$20,000 annual household income (yes) 243 (72)
 Illicit drug use in past 3 months (yes) 113 (34)
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Discussion
Our findings demonstrate that a brief survey question 
measuring self-reported undetectable VL strongly pre-
dicted true viral suppression, as confirmed via laboratory 
results, among a cohort of women living with HIV in BC, 
Canada. The PPV was high (>90) and the LR+  greater 
than 1, both for the overall sample and for specific sub-
populations, suggesting that this self-report measure is 
a valid method of assessment of undetectable VL among 
diverse communities of women living with HIV where 
VL testing is common and the true prevalence of viral 
suppression is high (i.e., 82% were undetectable as meas-
ured through laboratory data). The NPV was lower in 
comparison (ranging from 70 to 100 depending on the 
demographic group) but the LR− was extremely close to 
zero, suggesting that for participants who reported being 
detectable, we can have high confidence that this self-
report is accurate and the participant is not suppressed.
Jurisdictions around the world are currently imple-
menting policy and programmatic interventions to meet 
the United Nation’s 90–90–90 targets, which aim to have 
73% of all people living with HIV virally suppressed by 
2020 [11]. This goal has both individual and public health 
value, with HIV viral suppression achieved through early 
and sustained use of cART consistently shown to be asso-
ciated with reduced disease progression, extended life 
expectancy, and zero risk of onward transmission [2–9]. 
Measuring progress on achieving suppression in research 
settings is important but may be challenged by a lack of 
clinical data. We experienced this in CHIWOS, where 
only one of our three study provinces currently has labo-
ratory data available through linkage with a population-
based clinical registry.
As shown in this study, 82% of women living with HIV 
in BC had an undetectable VL, defined in this study as 
below 50 copies/mL, which exceeds the United Nation’s 
90–90–90 targets. Our threshold for designating a VL as 
undetectable was stricter than some studies (i.e., that use 
300 to 500 copies/mL [19]), but this cut-off is consistent 
with past reporting in Canada [20, 21], and even with this 
conservative measure, the prevalence of HIV suppres-
sion was high and comparable to observational data from 
other cohorts of women living with HIV [22, 23]. Moreo-
ver, based on the positive and negative predictive values 
Table 2 Predictive values and likelihood ratios of self-reported undetectable VL in overall CHIWOS cohort (n = 336)
PPV positive predictive value, NPV negative predictive value, LR+ positive likelihood ratio, LR− negative likelihood ratio, 95% CI 95 percent confidence interval, VL viral 
load, BC-CfE BC Centre for Excellence in HIV/AIDS, CHIWOS Canadian HIV Women’s Sexual and Reproductive Health Cohort Study
a Gold standard (True diagnosis)
PPV (95% CI) NPV (95% CI) LR+ (95% CI) LR− (95% CI)
Laboratory-confirmed VL (from BC-CfE)a
VL <50 copies/mL VL ≥50 copies/mL
Self-report VL (from CHIWOS)
 Undetectable (i.e. <50 copies/mL) 267 18 93.7 (90.2–96.2) 80.4 (66.9–90.2) 3.2 (2.1–4.6) 0.05 (0.03–0.10)
 Detectable (i.e. ≥50 copies/mL) 10 41
Table 3 Predictive values and likelihood ratios of self-reported undetectable VL in CHIWOS sub-populations (n = 336)
PPV positive predictive value, NPV negative predictive value, LR+ positive likelihood ratio, LR− negative likelihood ratio, 95% CI 95 percent confidence interval, VL viral 
load, CHIWOS Canadian HIV Women’s Sexual and Reproductive Health Cohort Study
PPV (95% CI) NPV (95% CI) LR+ (95% CI) LR− (95% CI)
Ethnicity
 Indigenous 92.6 (86.4–96.5) 86.7 (69.3–96.2) 3.8 (2.1–6.6) 0.05 (0.02–0.12)
 Caucasian 94.8 (89.1–98.1) 70.6 (44.0–89.7) 2.9 (1.5–5.5) 0.07 (0.03–0.16)
 African/Caribbean/Black 91.3 (72.0–98.9) 100.0 (29.2–100.0) 2.5 (0.8–7.3) NA
 Other 96.0 (79.6–99.9) 0 (0–97.5) 1.0 (0.9–1.0) NA
Education
 <High school 91.4 (82.3–96.8) 73.7 (48.8–90.9) 3.1 (1.6–6.1) 0.10 (0.04–0.25)
 ≥High school 91.4 (82.3–96.8) 84.4 (67.2–94.7) 3.4 (2.1–5.6) 0.03 (0.01–0.08)
Illicit drug use in past 3 months
 Yes 90.4 (81.9–95.8) 80.0 (61.4–92.3) 3.7 (2.0–6.8) 0.10 (0.04–0.22)
 No 95.0 (91.0–97.6) 80.1 (58.1–94.6) 2.6 (1.6–4.3) 0.03 (0.01–0.09)
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and likelihood ratios, the majority of women were able 
to accurately report their VL. This self-reported meas-
ure can, therefore, be used in research settings without 
laboratory data confirmation and where VL testing and 
the true prevalence of viral suppression is high to assess 
90–90–90-related goals.
There are limitations to this study. We were unable 
to validate this measure across all study provinces and 
women in different regions do differ in health and social 
characteristics. For instance, a much larger proportion 
of women identify as African, Caribbean or Black in 
Ontario (32%) and Québec (46%) compared with BC 
(8%) where more women identify as Indigenous (45%) 
and have histories of injection drug use (BC—63% vs. 
Ontario—19% vs. Québec—23%)  (data not shown). 
Women in Ontario are also younger, with a median 
age of 41 (IQR 34–49) versus 44 in BC (IQR 37–51) 
and 46 in Québec (IQR 38–53), and are less likely to 
be currently on cART (BC–89% vs. Ontario—75% vs. 
Québec—92%) with a self-reported undetectable VL 
(BC—80% vs. Ontario—71% vs. Québec—87%)  (data 
not shown). However, the current analysis demon-
strated high PPVs for the overall sample and specific 
sub-populations including women of varying ethnici-
ties and drug use histories. The range in NPVs was 
lower and wider depending on demographics charac-
teristics; thus, confidence in the true negative rate may 
vary by key factors such as education as shown in this 
analysis.
Another limitation is that we notified women dur-
ing the screening process that we would be asking for 
their clinical information. Thus, the high validity here is 
likely not just a result of women knowing their VL but 
also because some women accessed this information 
from their clinic before the actual study visit. This is per-
haps particularly true for women interviewed in a clinic 
setting. To examine this, we ran a sub-analysis among 
women who self-reported that their primary site of HIV 
medical care was Oak Tree Clinic [n = 132 (39% of sam-
ple)], one-third of whom were interviewed onsite [n = 41 
(31%)], versus women who did not access this clinic. The 
PPVs for these two groups were similar [Oak Tree Clinic: 
95.4 (95% CI 89.6–98.5) vs. Non-Oak Tree Clinic: 92.6 
(85% CI 87.6–96.0)]. However, the NPVs were much 
higher for Oak Tree Clinic patients [91.3 (95% CI 72.0–
98.9)] compared with non-Oak Tree Clinic patients [71.4 
(95% CI 51.3–86.8)]. Thus, while prompting participants 
for clinical information does not appear to have altered 
the proportion of those undetectable that are able to cor-
rectly identify as such, likely given the high VL  sup-
pression rates to begin with, these data  do suggest this 
screening procedure may have impacted accurate report-
ing of a detectable VL.
Finally, we also conducted a sub-analysis to deter-
mine whether the 18 participants who were unable to 
self-report their VL (either because they reported “don’t 
know”, “prefer not to answer”, or “never received care/VL 
results”) and thus excluded from this analysis were more, 
less, or equally likely to be undetectable than those who 
were included. Among these participants, 56% (n =  10) 
were detectable. This compares to only 18% (n = 59) of 
those were included in this analysis. It is possible that 
these women did not feel comfortable sharing this per-
sonal information or were simply unaware owing to com-
peting life demands preventing access to and engagement 
in care. All of these limitations are important to consider 
in research assessing VL levels.
Engagement in treatment, care, and support is critical to 
sustained viral suppression, and, in turn, improved indi-
vidual health and HIV prevention [4–9]. Future research 
will be conducted by our team to assess the prevalence 
and predictors of HIV clinical outcomes in this cohort, 
the largest study of women living with HIV in Canada.
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